Oral immunization of mice with recombinant Lactococcus lactis  expressing porcine transmissible gastroenteritis virus spike  glycoprotein.
Lactococcus lactis NZ9000 was selected as an antigen delivery vehicle for mucosal immunization against porcine transmissible gastroenteritis virus (TGEV) infection. An approximately 70 kDa fragment of the N-terminal globular domain of the spike (S) protein (SN protein) from the coronavirus TGEV was used as the transmissible gastroenteritis virus antigen model. Recombinant L. lactis, expressing the SN protein, was constructed with the pNZ8112 plasmid. Expression and localization of the transcribed SN protein from the recombinant LNZ9000- rTGEV-SN were detected via SDS-PAGE, Western blot, and immunofluorescence. BALB/c mice, orally immunized with LNZ9000-rTGEV-SN, produced local mucosal immune responses against TGEV. The induced antibodies demonstrated neutralizing effects on TGEV infection. These data indicated that the recombinant L. lactis could be a valuable tool in the development of future vaccines against TGEV.
Tang
Lijie
L
Life Science Department, Northeast Agricultural University, Harbin 150030, People's Republic of China.
Li
Yijing
Y
D000284:Administration, Oral; D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D004337:Drug Carriers; D004797:Enzyme-Linked Immunosorbent Assay; D005822:Genetic Vectors; D007413:Intestinal Mucosa / Q000276:immunology; D013294:Lactococcus lactis / Q000235:genetics*; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D044967:Serum / Q000276:immunology; D064370:Spike Glycoprotein, Coronavirus; D005760:Transmissible gastroenteritis virus / Q000235:genetics / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D004337:Drug Carriers; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D064370:Spike Glycoprotein, Coronavirus; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus